TNF and interstitial lung disease: However, given that the blood of SSc patients is enriched for this cytokine (Pehlivan et al., 2012), particularly among those with lung disease (Murdaca et al., 2014), as well as the availability of several FDA-approved TNFα inhibitors, the indication for these agents in SSc-ILD have been explored.